Table 2.
Basic characteristics of MaxART participants at the time of trial enrolment
| Standard of Care (n = 2034) | EAAA (n = 1371) | All ART naïve (n = 3405) | |
|---|---|---|---|
| Demographic characteristics | |||
| Age at trial enrolment (year) median (q1, q3) | 33 (28, 42) | 33 (27, 40) | 33 (27, 41) |
| Age group (years) n (%) | |||
| 18 to <20 | 40 (2%) | 34 (3%) | 74 (2%) |
| 20 to <30 | 679 (33%) | 472 (34%) | 1151 (34%) |
| 30 to <40 | 722 (36%) | 500 (36%) | 1222 (36%) |
| 40 to <50 | 354 (17%) | 230 (17%) | 584 (17%) |
| 50 to <60 | 156 (8%) | 97 (7%) | 253 (7%) |
| 60+ | 83 (4%) | 38 (3%) | 121 (4%) |
| Sex n (%) | |||
| Male | 695 (34%) | 603 (44%) | 1298 (38%) |
| Female | 1339 (66%) | 768 (56%) | 2107 (62%) |
| Marital status n (%) | |||
| Married | 1045 (52%) | 634 (48%) | 1679 (51%) |
| Divorced/widowed | 127 (7%) | 78 (6%) | 205 (6%) |
| Single | 825 (41%) | 614 (46%) | 1439 (43%) |
| Marital status missing, n (%) | 37 (2%) | 45 (3%) | 82 (2%) |
| Education n (%) | |||
| Illiterate/primary | 589 (40%) | 384 (38%) | 973 (39%) |
| Secondary | 438 (30%) | 362 (36%) | 800 (32%) |
| High school | 401 (27%) | 218 (22%) | 619 (25%) |
| Tertiary | 48 (3%) | 37 (4%) | 85 (4%) |
| Education missing, n (%) | 558 (27%) | 370 (27%) | 928 (27%) |
| Clinical characteristics a | |||
| BMI (kg/m2) n (%) | |||
| <18.5 | 82 (4%) | 81 (6%) | 163 (5%) |
| 18.5 to <25 | 971 (49%) | 762 (57%) | 1733 (52%) |
| 25 to <30 | 529 (27%) | 281 (21%) | 810 (25%) |
| ≥30 | 387 (20%) | 212 (16%) | 599 (18%) |
| BMI missing n (%) | 65 (3%) | 35 (3%) | 100 (3%) |
| CD4 (cells/μL) n (%) | |||
| <350 | 804 (44%) | 632 (56%) | 1436 (49%) |
| 350 to 500 | 441 (24%) | 224 (20%) | 665 (22%) |
| >500 | 591 (32%) | 266 (24%) | 857 (29%) |
| CD4 missing n (%) | 198 (10%) | 249 (18%) | 447 (13%) |
| WHO stage n (%) | |||
| 1 | 1074 (63%) | 800 (63%) | 1874 (63%) |
| 2 | 357 (21%) | 320 (25%) | 677 (23%) |
| 3 or 4 | 264 (16%) | 146 (12%) | 410 (14%) |
| WHO stage missing n (%) | 339 (17%) | 105 (8%) | 444 (13%) |
| Screened for TB symptoms n (%) | |||
| Positive | 190 (10%) | 100 (8%) | 290 (9%) |
| Missing screening for TB symptoms n (%) | 82 (4%) | 66 (5%) | 148 (4%) |
| Viral load (copies/ml) n (%) | |||
| <1000 | 229 (12%) | 120 (10%) | 349 (11%) |
| 1000 to <50‚000 | 781 (42%) | 479 (40%) | 1260 (41%) |
| 50‚000 to <100‚000 | 213 (11%) | 150 (13%) | 363 (12%) |
| ≥100‚000 | 661 (35%) | 438 (37%) | 1099 (36%) |
| Viral load missing n (%) | 150 (7%) | 184 (13%) | 334 (10%) |
| Time between positive HIV test to trial enrolment (years) n (%) | |||
| ≤1 | 1189 (59%) | 1076 (79%) | 2265 (67%) |
| 1 to ≤3 | 421 (21%) | 134 (10%) | 555 (16%) |
| >3 | 413 (20%) | 144 (11%) | 557 (17%) |
| Time from trial enrolment to ART initiation (months), median (q1, q3) | 11 (5, 16) | 0 (0, 0) | 7 (0, 88) |
| Access to HIV Treatment supporter n (%) | |||
| Yes | 1980 (97%) | 1339 (98%) | 3319 (97%) |
| Clinic characteristics | |||
| Level of clinic n (%) | |||
| Hospital | 449 (22%) | 349 (26%) | 798 (23%) |
| Clinic with maternity ward | 317 (16%) | 181 (13%) | 498 (15%) |
| Clinic without maternity ward | 1268 (62%) | 841 (61%) | 2109 (62%) |
| Clinic volume by ART visits at baseline b n (%) | |||
| < Median (400 visits) | 915 (45%) | 385 (28%) | 1300 (38%) |
| ≥ Median (400 visits) | 1119 (55%) | 986 (72%) | 2105 (62%) |
a
Values within 90 days of enrolment and before ART initiation
b
ART participant visits received during the first quarter into trial. Median number of visits during this period is 400.